J&J's Monarch lung robot gains FDA clearance for AI planning tools

Johnson & Johnson's Monarch bronchoscopy robot has been a cornerstone of the company's robotics strategy since its 2019 acquisition of Auris Health. As the first robotic bronchoscopy platform to reach market, Monarch established J&J's position in minimally invasive lung diagnostics. The Quest 3 update reflects the company's commitment to advancing the platform through frequent software iteration—four major releases in 18 months signals aggressive development. The addition of AI-driven planning and enhanced navigation tools addresses a core clinical need: helping physicians more quickly and accurately locate and sample suspicious lung nodules for cancer diagnosis.

The timing of this clearance also reflects J&J's broader expansion in robotic surgery. The company's recent FDA authorization for Ottava, a soft tissue robotic system targeting general surgery, shows J&J is competing across multiple surgical domains—Ottava will face off against Intuitive's established da Vinci platform and Medtronic's newer Hugo system. Together, these moves position J&J to capture share in a growing market for surgical and diagnostic robotics, where precision, ease of use, and clinical outcomes increasingly drive adoption.